6-chloro-2'-cyclohexylamino[2,4']bipyridinyl-4-carboxylic acid methyl ester | 1201675-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-chloro-2'-cyclohexylamino[2,4']bipyridinyl-4-carboxylic acid methyl ester
• 英文别名: 6-chloro-2'-cyclohexylamino-[2,4']bipyridinyl-4-carboxylic acid methyl ester；methyl 2-chloro-6-[2-(cyclohexylamino)pyridin-4-yl]pyridine-4-carboxylate
• CAS: 1201675-17-3
• 化学式: C₁₈H₂₀ClN₃O₂
• 分子量: 345.829
• InChiKey: HREIASOEFOQNGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-2'-cyclohexylamino[2,4']bipyridinyl-4-carboxylic acid methyl ester 、 t-butyl piperidin-3-ylcarbamate 在 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 C₂₈H₃₉N₅O₄
  参考文献：
  名称：

  Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D

  摘要：

  The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.

  DOI：

  10.1021/jm100076w
• 作为产物：
  描述：

  2,6-二氯异烟酸甲酯 、 2-cyclohexylamino-4-iodopyridine 在 四(三苯基膦)钯 、 六甲基二锡 、 二(三叔丁基膦)钯 、 cesium fluoride 作用下， 以 甲苯 、 1,4-二氧六环 为溶剂， 生成 6-chloro-2'-cyclohexylamino[2,4']bipyridinyl-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D

  摘要：

  The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.

  DOI：

  10.1021/jm100076w

文献信息

• [EN] 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER<br/>[FR] COMPOSÉS DE 2,4'-BIPYRIDINYLE COMME INHIBITEURS DE LA PROTÉINE KINASE D UTILES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE ET DU CANCER
  申请人：NOVARTIS AG

  公开号：WO2009150230A1

  公开（公告）日：2009-12-17

  The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.

  本发明提供了式I的新型有机化合物：其使用方法和药物组合物。
• ORGANIC COMPOUNDS
  申请人：Burgis Robin

  公开号：US20110092505A1

  公开（公告）日：2011-04-21

  The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.

  本发明提供了一种新型有机化合物I的方法，以及其使用方法和制药组合物。
• 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER
  申请人：Novartis AG

  公开号：EP2310381A1

  公开（公告）日：2011-04-20
• Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D
  作者：Erik L. Meredith、Kimberly Beattie、Robin Burgis、Michael Capparelli、Joseph Chapo、Lucian DiPietro、Gabriel Gamber、Istvan Enyedy、David B. Hood、Vinayak Hosagrahara、Charles Jewell、Keith A. Koch、Wendy Lee、Douglas D. Lemon、Timothy A. McKinsey、Karl Miranda、Nikos Pagratis、Dillon Phan、Craig Plato、Chang Rao、Olga Rozhitskaya、Nicolas Soldermann、Clayton Springer、Maurice van Eis、Richard B. Vega、Wanlin Yan、Qingming Zhu、Lauren G. Monovich

  DOI：10.1021/jm100076w

  日期：2010.8.12

  The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.